Abstract
Purpose. The objective was to evaluate the degradation profile of the elastase inhibitor DMP 777 and lay the foundation for formulation development.
Methods. The pKa was determined by potentiometric titration in mixed-aqueous solvents. The degradation kinetics were studied as a function of pH, buffer concentration, ionic strength, methanol concentration and temperature using a stability-indicating HPLC assay. The degradation products were identified by LC-MS, NMR, and by comparison with authentic samples.
Results. The pKa for the protonated piperazine nitrogen was estimated to be 7.04. The pH-rate profile is described by specific acid-, water-, and specific base-catalyzed pathways. The pH of maximum stability is in the range of 4 to 4.5 where water is the principal catalyst in the reaction. Buffer catalysis, primary salt effects and medium effects were observed. The proposed mechanism for acid catalyzed degradation is the rarely observed AAL1 which involves alkyl-nitrogen heterolysis. The driving force for the reaction appears to lie in the stability of the benzylic carbocation. The proposed mechanism for base catalyzed degradation is BAC2 which involves β-lactam ring opening. The β-lactam ring of DMP 777, a monolactam, appears to be as reactive as that in benzylpenicillin in the k OH controlled region where a similar mechanism of hydrolysis should be operative. A contributing factor to this increased reactivity may lie in the reduced basicity of the β-lactam nitrogen making it a good leaving group.
Conclusions. The degradation profile indicates that development of a solution dosage form of DMP 777 with adequate shelf-life stability at room temperature is feasible.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
H. L. Malech and J. I. Gallin. N. Engl. J. Med. 317:687–694 (1987).
S. J. Weiss. N. Engl. J. Med. 320:365–376 (1989).
J. P. Doherty, C. P. Dorn, P. L. Durette, P. E. Finke, M. Maccoss, S. G. Mills, S. K. Shah, J. J. Hale, T. J. Lanza and W. K. Hagmann. PCT application, Merck & Co., Inc., USA, WO 94/10142 (1994); European patent, 0 595 557 A1 (1994).
A. Albert and E. P. Serjent. Determination of Ionization Constants. 3rd ed., Chapman and Hall, New York, (a) pp. 14–38; (b) p. 11 (1984).
CRC Handbook of Chemistry and Physics. 73rd ed., D. R. Lide (ed.), CRC Press, Boca Raton, p. 8–42 (1992).
C. S. Handloser, M. R. Chakrabarty, and M. W. Mosher. J. Chem. Educ. 50:510–511 (1973).
J. T. Carstensen. J. Pharm. Sci. 59:1140–1143 (1970).
K. A. Connors. Chemical Kinetics: The study of reaction rates in solution. VCH publishers, New York, (a) pp. 410–412; (b) pp. 408–410 (1990).
R. N. Lacey. J. Chem. Soc. 1633–1639 (1960).
C. K. Ingold. 2nd ed., Cornell University Press, Ithaca, NY, pp. 1129–1131 (1969).
L. L. Schaleger and F. A. Long. Adv. Phys. Org. Chem. 1:1–31 (1963).
A. R. Butler, K. A. Freeman, and D. E. Wright. In J. Elks (ed.), Recent Advances In The Chemistry Of β-Lactam Antibiotics, The Chemical Society, Burlington House, London pp. 299–303 (1976).
R. B. Woodward. In H. T. Clarke, J. R. Johnson, and R. Robinson (eds.), The Chemistry of Penicillins, Princeton University press, Princeton, p. 443 (1949).
P. Finholt, G. Jurgensen, and H. Kristiansen. J. Pharm. Sci. 54:387–393 (1965).
N. P. Gensmantel, D. McLellan, J. J. Morris, M. I. Page, P. Procter, and G. S. Randahawa. In G. I. Gregory (ed.), Recent Advances In The Chemistry Of β-Lactam Antibiotics, The Royal Society of Chemistry, Burlington House, London, pp. 227–239 (1980).
G. M. Blackburn and J. D. Plackett. J. C. S. Perkin II, 1366–1371 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Raghavan, K.S., Gray, D.B., Scholz, T.H. et al. Degradation Kinetics of BMP 777, an Elastase Inhibitor. Pharm Res 13, 1815–1820 (1996). https://doi.org/10.1023/A:1016076907072
Issue Date:
DOI: https://doi.org/10.1023/A:1016076907072